{"id":10914,"date":"2025-10-10T12:00:30","date_gmt":"2025-10-10T17:00:30","guid":{"rendered":"https:\/\/ibio.org\/?p=10914"},"modified":"2025-10-10T12:00:30","modified_gmt":"2025-10-10T17:00:30","slug":"setting-the-record-straight-on-340b-in-illinois","status":"publish","type":"post","link":"https:\/\/ibio.org\/setting-the-record-straight-on-340b-in-illinois\/","title":{"rendered":"Setting the Record Straight on 340B in Illinois"},"content":{"rendered":"

There\u2019s been a lot of misinformation circulating about the 340B Drug Pricing Program and HB2371 in Illinois. Let\u2019s separate fact from fiction.<\/strong><\/h2>\n

 <\/p>\n

We\u2019ve been hearing some wild claims from hospital lobbying groups about what will happen if HB2371 doesn\u2019t pass. Here\u2019s what you need to know:<\/strong><\/h4>\n

 <\/p>\n

CLAIM:<\/strong> \u201cVoting NO on HB2371 will end the 340B program and force hospitals to close.\u201d<\/span><\/p>\n

FACT<\/strong>: The 340B program is a federal program that will continue to operate exactly as it does today, regardless of any state legislation. No state law can end a federal program.<\/span><\/p><\/blockquote>\n

\n


\nCLAIM<\/span><\/strong>: \u201c340B hospitals need this expansion to survive and serve vulnerable patients.\u201d<\/span><\/p>\n

FACT:<\/strong> Recent comprehensive analysis shows that after enrolling in 340B, hospitals:<\/span><\/p>\n

    \n
  • Increased financial investments by 89% per bed (stocks, bonds, financial instruments)<\/span><\/li>\n
  • Directed one-third of every 340B dollar to investment portfolios<\/span><\/li>\n
  • Decreased uncompensated care by 22% per bed<\/span><\/li>\n
  • Kept staffing completely flat despite massive revenue growth<\/span><\/li>\n<\/ul>\n

    In Illinois specifically, charity care at 340B hospitals plummeted from 4.80% to 2.14% between 2012-2022 \u2013 that\u2019s 6.5% below the national average.<\/span><\/p><\/blockquote>\n

    \n


    \nCLAIM<\/span><\/strong>: \u201cPatients benefit from the 340B program.\u201d<\/span><\/p>\n

    FACT:<\/strong> The Congressional Budget Office\u2019s September 2025 report found \u201cno evidence that patients benefit from the program.\u201d Instead, CBO found that 340B drives up costs for taxpayers and incentivizes more expensive care settings.<\/span><\/p>\n

    THE REAL COST OF HB2371:<\/span><\/strong><\/p>\n

      \n
    • Illinois Medicaid has already lost $238.4 million in rebates due to 340B<\/span>HB2371 would cost an additional $52 million annually<\/span><\/li>\n
    • Total impact: Over $290 million in taxpayer dollars<\/span><\/li>\n
    • $16 of every $100 in 340B revenue goes to contract pharmacy middlemen \u2013 not patients<\/span><\/li>\n<\/ul>\n<\/blockquote>\n
      \n


      \nTHE BOTTOM LINE:<\/strong><\/h4>\n

      \nThe data is clear. 340B hospitals are building Wall Street investment portfolios while cutting charity care. HB2371 would expand this broken system at a cost of $290+ million to Illinois taxpayers \u2013 with zero transparency requirements and zero evidence of patient benefit.<\/h4>\n

      The 340B program will continue to operate whether or not HB2371 passes. The question is: should Illinois expand a program that enriches hospital portfolios and pharmacy middlemen instead of helping vulnerable patients?<\/h4>\n","protected":false},"excerpt":{"rendered":"

      There\u2019s been a lot of misinformation circulating about the 340B Drug Pricing Program and HB2371 in Illinois. Let\u2019s separate fact from fiction.   We\u2019ve been hearing some wild claims from hospital lobbying groups about what will happen if HB2371 doesn\u2019t pass. Here\u2019s what you need to know:   CLAIM: \u201cVoting NO on HB2371 will end […]<\/p>\n","protected":false},"author":12,"featured_media":10922,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[146],"tags":[693,121],"class_list":["post-10914","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-policy-news","tag-340b","tag-illinois"],"_links":{"self":[{"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/posts\/10914","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/comments?post=10914"}],"version-history":[{"count":9,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/posts\/10914\/revisions"}],"predecessor-version":[{"id":10928,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/posts\/10914\/revisions\/10928"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/media\/10922"}],"wp:attachment":[{"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/media?parent=10914"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/categories?post=10914"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/tags?post=10914"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}